GlassScriptPhysician profile
Katie Dunkel
NPI 1447485727
$1,551.35
in general payments reported to CMS, 2019-2025
24 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $369 · 2022: $432 · 2023: $288 · 2024: $344 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $486.28 | 2021-2025 | |
| Lilly USA, LLC | $160.45 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $141.55 | 2021-2025 | |
| Novo Nordisk INC | $127.59 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $98.91 | 2022-2024 | Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.67 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.60 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.00 | 2022 | |
| Abbott Laboratories | $49.73 | 2022-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $41.65 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.95 | 2021 | |
| Boston Scientific Corporation | $28.15 | 2021-2023 | Watchman Access System |
| Procept Biorobotics Corporation | $23.29 | 2024 | Aquabeam System |
| Hologic Sales and Service, LLC | $23.14 | 2023 | Aptima |
| Nestle Healthcare Nutrition INC. | $20.93 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $20.26 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $17.65 | 2021 | |
| Glaxosmithkline, LLC. | $17.47 | 2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $16.87 | 2025 | Rexulti |
| Amgen INC. | $16.15 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.22 | 2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $14.15 | 2023 | |
| Sunovion Pharmaceuticals INC. | $12.55 | 2021 | |
| Redhill Biopharma INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Dunkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.